Breast? likely no: The primary trial of Raloxifene for breast chemoprevention was limited to 5 years of use to match the standard of 5 years of tamoxifen. Recent data suggest a benefit of 10y of tam over 5 years for treatment of invasive er+ breast cancer. However, the benefit of the extra five years is not seen until after year 10. That suggests that the benefit of that drug holds for 5 years after it is stopped.
Answered 12/4/2018
5.3k views
A doctor has provided 1 answer
A doctor has provided 1 answer
6 doctors weighed in across 2 answers
3 doctors weighed in across 2 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question